Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Prodrug, preparation method therefor, pharmaceutical compositions and use thereof

A prodrug and compound technology, applied in the field of anti-hepatitis C drugs, can solve the problems of large side effects and high treatment costs

Active Publication Date: 2017-06-23
HANGZHOU HERTZ PHARMA
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This type of treatment has side effects, including depression, fatigue, flu-like symptoms, and anemia; the cost of treatment is high, and the standard course of treatment takes 48 weeks, costing about US$40,000

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prodrug, preparation method therefor, pharmaceutical compositions and use thereof
  • Prodrug, preparation method therefor, pharmaceutical compositions and use thereof
  • Prodrug, preparation method therefor, pharmaceutical compositions and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0126] Embodiment 1: the synthesis of compound II-A-1

[0127] Method A:

[0128]

[0129] Step 1: Dissolve 529mg (1.0mmol) III-1 in 10mL of anhydrous acetone, add 680mg (1.5mmol) IV-A-1 and 414mg (3.0mmol) potassium carbonate at room temperature, heat, stir and reflux for 6h, and detect the reaction by TLC completely. After filtration, the filtrate was diluted with dichloromethane (30 mL), washed with water (10 mL) and saturated brine (10 mL) successively, the organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography to obtain 710 mg of white solid V-A-1, with a yield of 75%, ESI-MS: m / z[M+H] + =947.

[0130] Step 2: Dissolve 200mg (0.21mmol) V-A-1 in 10mL of anhydrous dichloromethane, add 2mL at room temperature (volume ratio: dichloromethane / triisopropylsilane / trifluoroacetic acid=5 / 1 / 1) Solution, reacted for about 1 h, TLC det...

Embodiment 2

[0137] Embodiment 2: the synthesis of compound II-A-1a

[0138]

[0139] Compound VII-1 was freshly prepared according to step 1 of method B in Example 1 (3 mmol of compound III-1 as the starting material), dissolved in 12 mL of anhydrous dichloromethane (DCM), cooled in an ice bath under argon protection, Add 18 mg (0.15 mmol) 4-dimethylaminopyridine (DMAP) and 0.75 g (3.9 mmol) 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC HCl) in sequence , and 1.93g (3.6mmol) compound VIII-A-1a (prepared by chiral tiopronin, R configuration chiral purity 95%, analysis method: AD-H column temperature: 25C; detection wavelength: 210nm; flow rate : 1.0ml / min; mobile phase: n-Hex:EtOH:TFA=90:10:0.1 isocratic elution), then slowly rise to room temperature and stir the reaction for about 12 hours, and TLC detects that the reaction is complete. Add 30 mL of dichloromethane, wash with saturated aqueous sodium bicarbonate solution and saturated brine successively, separate the...

Embodiment 3

[0141] Embodiment 3: the synthesis of compound II-A-1b

[0142]

[0143] According to step 1 and step 2 in method B of Example 1, use VIII-A-1b (prepared from chiral tiopronin, S configuration chiral purity 97%, analysis method: AD-H column temperature: 25C; detection Wavelength: 210nm; flow rate: 1.0ml / min; mobile phase: n-Hex:EtOH:TFA=90:10:0.1 isocratic elution) instead of VIII-A-1a, 5.3g (10mmol) compound III-1 can 2.57 g of intermediate IX-A-1b were prepared in 72% yield (two steps).

[0144] According to Step 3 in Method B of Example 1, compound IX-A-1b (2.9 mmol) was further deprotected to obtain 1.04 g of white solid product II-A-1b with a yield of 84%. ESI-MS:m / z[M+H] + =705.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a nucleoside structure containing prodrug represented by a formula I shown in the description or tautomers, stereomers, stereomer mixtures or pharmaceutically-acceptable solvates thereof and simultaneously discloses preparation methods for the prodrug or the tautomers, stereomers, stereomer mixtures or pharmaceutically-acceptable solvates thereof, pharmaceutical compositions prepared from the prodrug or the tautomers, stereomers, stereomer mixtures or pharmaceutically-acceptable solvates thereof and use of the pharmaceutical compositions as hepatitis C resisting drugs. The compounds or pharmaceutical compositions thereof can be applied to the treatment of hepatitis C and meanwhile play roles in protecting hepatic tissue and hepatic cells, improving hepatic functions, reducing aminopherase, and the like.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry. Specifically, the present invention relates to a compound represented by the following general formula I or its tautomers, stereoisomers, stereoisomer mixtures, prodrugs, pharmaceutically acceptable salts or solvates thereof , its preparation method, pharmaceutical composition and its use as anti-hepatitis C medicine. Background technique [0002] Hepatitis C is a liver disease caused by hepatitis C virus (hereinafter referred to as HCV), which seriously threatens human health. In 1978, hepatitis C virus was discovered for the first time; in 1989, the gene sequence was determined, and HCV was confirmed as another major pathogen of non-A and non-B hepatitis. According to the heterogeneity of HCV genome, it can be divided into 6 types and 30 subtypes. The type of infection has strong regional characteristics, and type 1 is the main type in my country. A study in 2011 showed that among Chinese...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07H19/10C07H1/00A61K31/7072A61P31/14C07C323/59C07C323/60
CPCA61K31/7072A61K45/06C07B2200/13C07C323/58C07C323/59C07C323/60C07H1/00C07H19/10Y02P20/55
Inventor 周星露刘兴国董晓武
Owner HANGZHOU HERTZ PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com